3-hydroxy-7α-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene | 229634-97-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-hydroxy-7α-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene
• 英文别名: 3-Hydroxy-7α-methyl-21-[2'-methoxy-4'-(N,N-diethylaminomethyl)phenyloxy]-19-norpregna-1,3,5(10)-triene；TAS-108；Unii-42U0C8volo；(7R,8S,9S,13R,14S,17R)-17-[2-[4-(diethylaminomethyl)-2-methoxyphenoxy]ethyl]-7,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol
• CAS: 229634-97-3
• 化学式: C₃₃H₄₇NO₃
• 分子量: 505.741
• InChiKey: OHCPNHFLPCVWRG-MWSJHZLTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Fused heterocyclic compounds
  申请人：Johnson A. James

  公开号：US20050250783A1

  公开（公告）日：2005-11-10

  A compound of formula I wherein m, n, A, B, D, E, G, H, Y, R 1 , R 2 , R 3 , R 4 , R 5 , and R 8 , are described herein.

  其中m、n、A、B、D、E、G、H、Y、R1、R2、R3、R4、R5和R8在本发明中有所描述。
• Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
  申请人：——

  公开号：US20020032180A1

  公开（公告）日：2002-03-14

  Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

  提供了新型抗雌激素化合物，这些化合物可用于治疗各种疾病，特别是依赖雌激素的疾病。优选的化合物具有1,3,5-雌三烯骨架，并在C-17或C-11位置上取代了一种分子基团，使这些化合物能够有效地竞争性地阻断雌激素与其受体的结合。特别优选的化合物是17-去氧-1,3,5-雌三烯。还提供了治疗方法和药物组合物。
• Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
  申请人：——

  公开号：US20020032181A1

  公开（公告）日：2002-03-14

  Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

  提供了一种新型的抗雌激素化合物，可用于治疗多种疾病，特别是雌激素依赖性疾病。首选化合物具有1,3,5-雌三烯核，且在C-17或C-11位置被取代为分子基团，使化合物能够有效地竞争性地阻止雌激素与其受体的结合。特别优选的化合物是17-去氧-1,3,5-雌三烯。同时提供了治疗方法和制药组合物。
• FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION
  申请人：Johnson James A.

  公开号：US20100247534A1

  公开（公告）日：2010-09-30

  A compound of formula I wherein m, n, A, B, D, E, G, H, Y, R 1 , R 2 , R 3 , R 4 , R 5 , and R 8 , are described herein.

  这是一个化学式，公式为I，其中m，n，A，B，D，E，G，H，Y，R1，R2，R3，R4，R5和R8在此被描述。
• novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
  申请人：Sri International

  公开号：EP1310509A2

  公开（公告）日：2003-05-14

  Novel and anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependant disorders. Preferred compounds have 1,3,5-estratiene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratienes. Therapeutic methods and pharmaceutical compositions are provided as well.

  本研究提供了新型抗雌激素化合物，可用于治疗各种疾病，特别是雌激素依赖性疾病。优选的化合物具有 1,3,5-雌甾二烯核，并在 C-17 或 C-11 位置被分子基团取代，从而使化合物能够有效地竞争性阻断雌激素与其受体的结合。特别优选的化合物是 17-脱氧-1,3,5-雌甾烯。此外，还提供了治疗方法和药物组合物。